An independent reading of the GHK-Cu literature

What GHK-Cu Buy is

GHK-Cu Buy is an independent editorial project that publishes summaries of the peer-reviewed research literature on GHK-Cu, the copper-binding tripeptide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The project exists because the copper-peptide literature is genuinely interesting and genuinely easy to overstate — a thirty-year body of in vitro and rodent work, a handful of small human topical trials, and a great deal of secondary commentary that blurs the line between the two ^[3][6]. This site reads the primary record and keeps that line visible.

What the name means

The word in the domain name is editorial framing, not a description of services. This project does not sell GHK-Cu, broker it, or point readers toward any source — the name marks a position the publisher occupies relative to the literature, the place a reader lands when they are weighing what the research actually says. There is no storefront here and no transaction of any kind.

We also draw a hard distinction the literature often blurs: Copper Tripeptide-1, the topical cosmetic ingredient, has a long safety record, while injectable or systemic GHK-Cu is an unapproved research chemical with no validated human pharmacokinetics ^[6]. Where this brief discusses systemic doses, it reports them as the parameters of a cited study in a named species — never as guidance for a person.

The editorial standard

Every quantitative claim on this site — every dose, percentage, n-value, molecular weight, and effect size — maps to a numbered citation in a real peer-reviewed study, review, or clearly labeled preprint ^[1][2][4]. Where the data is preclinical, we say preclinical; where it is a bioRxiv preprint, we label it; where human pharmacokinetics are simply absent, we mark the gap rather than fill it ^[8][14].

A particular caution runs through the GHK-Cu field: a large share of the foundational mechanistic and review literature originates from a single investigator group, so the broadest gene-expression and anti-aging claims await independent replication ^[2][6]. We surface that limitation rather than launder it, and we revise as the record changes.

The register here is deliberate. GHK-Cu's most eye-catching numbers — a peptide that reaches roughly a third of the human transcriptome, that improves cognition in aged mice — are exactly the kind that get rounded up into marketing copy ^[2][8]. An advisory brief is the right container for them: it can report each result at full strength and, in the same breath, mark the species, the route, and the absence of human data. That balance, held consistently across every page, is the standard this project is built to.